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Abstract
One of the major concerns of modern society is to identify putative biomarkers that serve as a valuable early diagnostic 
tool to identify a subset of patients with increased risk to develop neuropsychiatric disorders. Biomarker identification in 
neuropsychiatric disorders is proposed to offer a number of important benefits to patient well-being, including prediction of 
forthcoming disease, diagnostic precision, and a level of disease description that would guide treatment choice. Nowadays, 
the metabolomics approach has unlocked new possibilities in diagnostics of devastating disorders like neuropsychiatric 
disorders. Metabolomics-based technologies have the potential to map early biochemical changes in disease and hence 
provide an opportunity to develop predictive biomarkers that can be used as indicators of pathological abnormalities prior 
to development of clinical symptoms of neuropsychiatric disorders. This review highlights different -omics strategies 
for biomarker discovery in neuropsychiatric disorders. We also highlight initial outcomes from metabolomics studies in 
psychiatric disorders such as schizophrenia, bipolar disorder, and addictive disorders. This review will also present issues and 
challenges regarding the implementation of the metabolomics approach as a routine diagnostic tool in the clinical laboratory 
in context with neuropsychiatric disorders.
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Introduction
Millions of people undergo mental disorders such as major 
depressive disorder (MDD), bipolar disorder (BD), schizo-
phrenia (SCZ), and addiction. According to the World Health 
Organization, the worldwide problem of neuropsychiatric dis-
orders is 13% higher than others such as cardiovascular dis-
eases and cancer (WHO, 2008). Though significant improvement 
has been made in the treatment of neuropsychiatric disorders, 
numerous patients do not respond to current therapies, had an 
inadequate response, or are incapable to tolerate them.
Unfortunately, our understanding of pathophysiology of 
these disorders remains limited. One reason for this is the fact 
that most of mental disorders are not unitary conditions but may 
be a complex of psychopathological dimensions that are yet to 
be identified. In addition, present knowledge is also incomplete 
in predicting who will and who will not respond to a certain 
treatment. Such doubtfulness is worrying for patients and fami-
lies who are continually involved in trial-and error selections in 
search of “the right fit” and for clinicians thus resorting to exten-
sive substituting of medications (Weiden and Buckley, 2007) 
and polypharmacy (Tranulis et al., 2008). So, there is a further 
requirement to scale up awareness in the study of psychiatric 
disorders in an effort to recognize at a system level the entirety 
of alterations that can contribute to the pathogenesis of these 
environments. Disease-specific molecular fingerprinting can be 
well-defined by integrating the use of high-throughput meth-
odologies at the core of genomics, proteomics, metabolomics, 
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and other -omics approaches and could aid to map dysregulated 
systems involved in disease pathogenesis. Furthermore, global 
mapping of uncharacteristic pathways in psychiatric disor-
ders can lead to the identification of biomarkers of disease and 
response (Quinones and Kaddurah-Daouk, 2009).
This review summarizes general aspects of biomarker 
research and how metabolic abnormalities in psychiatric disor-
ders can contribute to the identification of distinctive biomark-
ers. We also discuss existing challenges and the potential of 
metabolic approaches in the process of biomarker discovery.
Biomarker Discovery Research
The use of the term “biomarker” dates back to as early as 
1980 (Jeffrey, 2005). In 1998, the National Institutes of Health 
Biomarkers Definitions Working Group described a biomarker as 
“a characteristic that is objectively measured and evaluated as 
an indicator of normal biological courses, pathogenic progres-
sions, or pharmacologic responses to a therapeutic interven-
tion” (Aronson, 2005; Strimbu and Tavel, 2010). In metabolomics, 
biomarkers can be measured in any biological sample, for exam-
ple, blood, urine, or saliva (Bogdanov et al., 2008; Holmes et al., 
2008b; Kaddurah-Daouk et  al., 2009) and can be indicators of 
disease traits (or risk markers), disease states, or disease rates 
(progression).
Biomarkers could be considered to extend all the way to 
include our fixed genomic characters. At the level of the sub-
cellular and tissue, the search has queried the transcriptomics, 
proteomics, metabolomics, lipidomics, immunological, and bio-
logical epigenetics (Figure 1). The recent attention in biomarker 
discovery is encouraged by new molecular biologic techniques 
with the ability to find relevant markers speedily without 
detailed perception into the mechanisms of a disease.
Biomarkers in Genomics
Mental disorders include a wide spectrum of diseases in the 
central nervous system (CNS), with symptoms varying from cog-
nitive dysfunction to alterations in emotions, thoughts, or per-
formance (Krystal and State, 2014). Due to the complex nature 
of brain disorders, it is unfruitful to find out the mechanisms 
using conventional methodologies, where only small pathways 
around specific target genes are examined. Recently, genomic 
technologies have been progressively applied to the investi-
gation of neuropsychiatric disorders (McCarroll et  al., 2014). 
Remarkably, genome-wide association studies (GWAS) have sig-
nificantly increased the knowledge of the genetic basis of psy-
chiatric disorders (Ozomaro et al., 2013; Luykx et al., 2015). GWAS 
are based on the fact that several single-nucleotide polymor-
phisms (SNPs) in a defined haplotype provide the same informa-
tion for association with a causal variant, thus decreasing SNPs 
to be tested for association. As most of the common SNPs are 
situated in genomic regions with no clear function (e.g., intronic 
areas or intergenic regions), identification of the fundamental 
“causal” variant or the identification of the related function 
needs further efforts. Many of the SNPs have been associated 
with predicting treatment response (both in terms of therapeu-
tic efficacy and side-effect profile) to a pharmacologic interven-
tion. One of the challenges for a successful GWAS in the future 
will be to apply the findings in a way that accelerates drug and 
diagnostics development as well as better integration of genetic 
studies into the drug-development process and a focus on the 
role of genetic variation in maintaining health as a blueprint for 
designing new drugs and diagnostics (Iadonato and Katze, 2009).
Lymphocyte gene expression profiling has emerged as a 
predominantly interesting area of research in the examina-
tion for peripheral biomarkers (Tsuang et al., 2005). Many stud-
ies have focused on human blood gene expression profiling, 
comparison between illness and healthy control groups, and 
cross-matching with human postmortem brain gene expres-
sion data (Le-Niculescu et  al., 2007). Iga et  al. (2007) studied 
peripheral gene expression before and after treatment of 
major depressed patients and reported high levels of histone 
deacetylase 5 and cyclic-AMP response element binding pro-
tein 1 prior to treatment, with a significant decrease follow-
ing 8 weeks of antidepressant treatment. de Jong et al. (2012) 
did a large peripheral gene expression study with medicated 
SCZ subjects (n = 92), unmedicated SCZ (n = 29), and 118 healthy 
controls. They focused on determining coexpression networks 
related with SCZ, nevertheless of treatment, in which they 
Figure 1. Schematic representation of various biological approaches for biomarker discovery in neuropsychiatric disorders.
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found that the most important network branched out from the 
ABCF1 gene, a gene controlled by the major histocompatibil-
ity complex, and placed in an SCZ-associated genetic region 
(Debnath et al., 2013). In 2005, Tsuang et al. found an 8-gene 
putative biomarker capable of discerning individuals with BD, 
SCZ, and controls with 95% accuracy using blood-based gene 
expression. Although most of the work has been placed toward 
purely genetic markers of treatment response (Cruceanu et al., 
2011; Narasimhan and Lohoff, 2012), genetic variation alone 
might not explain response, suggesting that other factors are 
possibly involved.
Biomarkers in Transcriptomics
Another methodology for current biomarker discovery in major 
psychiatric disorders is high-throughput microarray gene chips 
that include the whole human transcriptome and are capable 
of identifying mRNA abundances (eg, expression profiles). The 
examination for gene expression changes associated with SCZ 
is the most worn research path towards biomarker identifica-
tion (Pickard, 2015). In one study, whole blood was acquired from 
52 antipsychotic-naive SCZ patients and 49 healthy controls. 
Altogether, 792 differentially expressed genes were exposed 
through microarray analysis and the process of cell adhesion 
recognized as a significantly overrepresented gene ontology 
term within. A neural network method was then presumed in 
order to express a diagnostic set of genes (Takahashi et al., 2010). 
Another study of blood gene expression was reported in patients 
diagnosed with medicated SCZ subjects which were used as the 
basis for a diagnostic test and that was able to appropriately 
identify disease status in 89.3% and 70% of cases of SCZ and 
healthy controls, respectively (Maschietto et al., 2012).
In addition to the traditional mRNA arrays, a somewhat 
new and promising transcriptomic approach was established 
using microRNAs (miRNAs). miRNAs are small (approximately 
22 nucleotides) noncoding RNAs that perform cell and tissue 
regulatory functions pertaining to development and homeo-
stasis (Kocerha et  al., 2009). However, since the discovery of 
miRNAs (Lee et al., 1993), a limited amount of miRNA studies 
have been shown in major psychiatric disorders (Dwivedi, 2014). 
Much consideration has been given to the role of miRNAs, pre-
dominantly in SCZ (Perkins et al., 2007; Beveridge et al., 2008). 
miRNA data have recently been placed into the Gene Expression 
Omnibus presenting altered miRNA expression in the fron-
tal cortex of major depressive patients (NCBI accession num-
ber GSE17440). The number of miRNAs currently stands at 706 
according to the Sanger miRBase release 13.0 miRNA database 
(http://microrna.sanger.ac.uk/sequences) (Griffiths-Jones et  al., 
2008). This improvement in utilization and discovery is in part a 
result of recent development of miRNA microarrays by Illumina, 
Affymetrix, Applied Biosystems, and Agilent that are accom-
plished of searching all known human miRNAs at one time.
Biomarkers in Proteomics
In recent years, proteomics has appeared as a viable approach 
used not only to recognize novel diagnostic and therapeutic 
biomarkers but also to investigate clinical diagnostics and drug 
development for psychiatric disorders (Patel, 2014; Sethi et al., 
2015). Proteomics-based technologies for biomarker discovery 
have been encouraging, because changes in protein expression 
and its abundance, structure, or function can be used as indica-
tors of pathological abnormalities prior to expansion of clinical 
symptoms of neuropsychiatric disorders.
Genomics-based tools have provided important perceptions 
in neuroscience and psychiatry research, but when it comes to 
clinical use, it has been unsuccessful in progressing the diag-
nostic and therapeutic options in brain disorders (Hünnerkopf 
et al., 2007). On the contrary, using protein identification based 
on high-throughput mass spectrometric (MS) analysis, it is likely 
to unravel signal transduction pathways and complex interac-
tion networks on the level of proteins (Hünnerkopf et al., 2007). 
Research using the proteomics approach have largely enhanced 
our understanding of psychiatric disorders and identifyied its 
relevant biomarkers. Currently, new technologies like proteom-
ics-based approaches have made it possible to look into new 
perceptions in context with neuropsychiatric disorders, hence 
overwhelming standard targeted approaches (Martins-de-Souza 
et al., 2010a, 2010b). Quantitative and qualitative identification of 
protein patterns in postmortem brain tissue, cerebrospinal fluid 
(CSF), plasma, or serum using proteomic tools has improved the 
knowledge about etiology and path mechanisms of psychiatric 
diseases (Hünnerkopf et al., 2007). Interestingly, this approach 
established the first blood-based examination to aid in SCZ 
diagnosis, based on the identification of a set of molecular bio-
marker assays (Martins-de-Souza et  al., 2012). Recently, prot-
eomic analysis of first-episode SCZ patients after risperidone 
treatment in plasma samples investigated significant changes 
in apolipoprotein A-I and guanine nucleotide binding protein, 
alpha stimulating and proposed that apolipoprotein A-I might 
be a novel biomarker related to metabolic side effects in first-
episode SCZ patients treated with risperidone (Song et al., 2014).
A number of preclinical studies have also suggested that the 
brain-derived neurotrophic factor (BDNF), a well-established 
neurotrophin, plays an important role in the pathophysiology of 
numerous psychiatric disorders (Teche et al., 2013; Munkholm 
et  al., 2014; Akyol et  al., 2015) and regulates neuronal growth, 
survival, and function of the adult brain (Yukimasa et al., 2006; 
Calabrese et al., 2014). However, clinical investigations of BDNF in 
psychiatric disorders is contradictory. Some reports have stated 
reduced blood BDNF levels in patients with SCZ (Yang et  al., 
2011; Akyol et  al., 2015; XY Zhang et  al., 2015), BD (Machado-
Vieira et al., 2007; de Oliveira et al., 2009), and MDD (Sen et al., 
2008; Bocchio-Chiavetto et  al., 2010; Polyakova et  al., 2015), 
whereas others have confirmed opposite findings (Durany et al., 
2001; Jevtović et al., 2011; Munkholm et al., 2014). Nevertheless, 
some meta-analysis of case-control studies examined changes 
in BDNF following pharmacologic treatment in psychiatric dis-
orders (Goldstein and Young, 2013; Pagsberg et  al., 2014; Yan 
et al., 2014). Additional studies are needed to examine whether 
BDNF can inform our understanding, treatment, and prevention 
of aforesaid psychiatric disorders.
Biomarkers in Metabolomics
Metabolomics, the latest -omics strategy, offers powerful tools 
for describing perturbations in metabolic pathways and net-
works in human disease. Metabolomics has the potential to 
map early biochemical changes in disease and hence provides 
an opportunity to develop predictive biomarkers that can trig-
ger earlier interferences (Kaddurrah-Daouk et  al., 2008). In 
fact, metabolomics seems promising for the diagnosis and 
identification of key metabolic features that describe certain 
pathological and physiological states (Mamas et  al., 2011). 
Recent applications of metabolomics cover widespread areas, 
including: disease diagnosis, drug discovery and development 
(Gomase et al., 2008), pharmacometabolomics and personalized 
medicine (Kaddurah-Daouk et  al., 2008), nutrigenomics (Ryan 
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and Robards, 2006), and metabolic engineering/ biotechnology 
(Buchholz et al., 2002). The use of metabolomics in the exami-
nation for novel biomarkers in different clinical areas is based 
on the hypothesis that diseases cause disruption of biochemi-
cal pathways leading to a metabolic fingerprint characteristic of 
the site and nature of the disease (Lindon et al., 2003). In fact, 
metabolomic signatures have already been reported for several 
diseases (Table  1), including MDD (Huang and Lin, 2015), SCZ 
(Paredes et al., 2014; Pickard, 2015), cardiovascular and coronary 
artery disease (Rizza et al., 2014), diabetes (M Zhang et al., 2015), 
BD (McIntyre et al., 2014), drug addiction (Dinis-Oliveira, 2014), 
and also cancers (Xiang et al., 2015).
Another aspect of metabolomics as a tool for discovery of 
biomarkers is its ability to understand the relationships and 
interactions between metabolic state of an individual and envi-
ronmental aspects (diet, lifestyle, gut microbial activity, and 
genetics) under a particular set of conditions (Nicholson, 2006; 
Holmes et al., 2008a; Quinones and Kaddurah-Daouk, 2009) and 
provide metabolic phenotyping (metabotyping) in health and 
disease (Holmes et al., 2008b; Nicholson et al., 2012). For exam-
ple, GWAS have found associations between genotype variation 
and disease phenotypes (Adamski and Suhre, 2013), and, analo-
gously, the metabolome wide association (MWAS) has revealed 
associations of metabolic phenotypes with disease risk in the 
general population and relates these metabotypes to disease 
risk factors (Holmes et al., 2008a, 2008b). The main advantage of 
the MWAS approach is that the resulting biomarkers are genu-
ine metabolic endpoints, and investigations into these pathway 
perturbations may yield new therapeutic targets. Therefore, 
MWAS studies have the potential to provide new insights into 
disease mechanisms and pathophysiology that may ultimately 
lead to new drug targets.
Overall, metabolomics-based biomarkers should prove to be 
useful for disease diagnosis and screening, therapeutics toxicity 
and efficacy assessment, patient stratification, drug discovery, 
and monitoring of patient response to treatment (Griffiths et al., 
2010).
Biomarkers in Lipidomics
Lipidomics is the comprehensive analysis of molecular lipid spe-
cies with their quantitation and metabolic pathways (German 
et al., 2007). Since lipids maintain a diversity of biological func-
tions in the processes of life such as formation of cellular mem-
branes, energy storage, and cell signaling, they can be projected 
to reflect much of the metabolic status in health and disease 
(Gross and Han, 2006; Zhao et al., 2015). Up to now, several stud-
ies have revealed that lipidomics seems to be crucial in deter-
mining novel lipid molecular species that function as potential 
biomarkers in many lipid-related diseases. Comprehensive 
applications of lipidomics in the discovery of potential lipid bio-
markers have been carried out for certain metabolic diseases 
such as obesity (Yetukuri et al., 2007), diabetes (Han et al., 2007), 
cardiovascular disease (Brindle et al., 2002), and cancers (Tung 
et al., 2008). One of the most extensively used lipid biomarkers 
has been cholesterol, which, in the form of total blood choles-
terol and/or high density lipoprotein cholesterol, has been used 
in risk calculations for cardiovascular disease for more than 
50 years (Meikle et al., 2009).
In one study, Kaddurah-Daouk and colleagues (2007) used a 
specialized lipidomics platform and found alterations in differ-
ent lipid classes (phosphatidylcholine, phosphatidylethanola-
mine, triacylglycerol) were found in the plasma of SCZ patients 
after 2 to 3 weeks of treatment with atypical antipsychotic 
drugs. A  recent study has also demonstrated that significant 
downregulation of several n3 and n6 polyunsaturated fatty acid 
compositions in phosphatidylethanolamine and phosphatidyl-
choline lipid classes in the blood plasma of first-episode SCZ 
patients (McEvoy et  al., 2013). These changes in lipid metabo-
lism could indicate a metabolic vulnerability in patients with 
SCZ that occurs early in the development of the disease. Apart 
from applications in human diseases, the strategy of lipidomics-
driven biomarker discovery has also been used in fields of nutri-
tion and health necessary for health promotion and disease 
prevention (Draisma et al., 2008).
Biomarkers in Epigenetics
Epigenetics is the study of long-lasting modification of nuclear 
DNA (eg, methylation or nucleosome modification) that is often 
influenced by the environment and displays itself as changes 
in gene expression (Pickard, 2015). The new data fortune and 
knowledge relating to epigenetics obtained in recent years high-
lights an exciting future for epigenetics research. As more epi-
genetic marks are associated with specific diseases, tools can 
be advanced to improve diagnosis and assessment of severity 
of disease. There is also a great interest in therapeutic epigenet-
ics. Several drugs, such as DNA methyltransferase inhibitors and 
histone deacetylase inhibitors, are already used in cancer treat-
ment (Esteller, 2007).
The application of epigenetics for the detection and diagno-
sis of psychiatric disorders is a new and potentially promising 
area of research (Nishioka et al., 2012). Several lines of evidence 
obtained from such research suggest that the RELN gene, encod-
ing reelin, is epigenetically altered in patients with psychosis, 
resulting in reduced expression of reelin (Peedicayil, 2007). 
Reelin is an extracellular matrix glycoprotein that is involved in 
guiding neurons and radial glial cells to their correct positions 
in the developing brain and in neurotransmission, memory for-
mation, and synaptic plasticity in the adult brain (Fatemi, 2005).
Biomarkers in the Immune System
Considered as the hormones of the immune system, cytokines 
play a significant role in infection and inflammation and are key 
signaling molecules of the immune system that exert effects in 
the CNS and immune system. Modifications in the cytokine net-
work could be related to the pathophysiology of neuropsychiatric 
disorders or even its etiology. Numerous hypotheses exist regard-
ing aberrant levels of proinflammatory cytokines in the serum, 
plasma, and CSF of patients with SCZ and major mood disorders 
(Dowlati et al., 2010; Miller et al., 2011; Kalia et al., 2015; Pickard, 
2015). Potvin et  al. (2008) suggested a T helper Type 1/T helper 
Type 2 (Th1/Th2) disproportion hypothesis wherein an increase 
in in vivo peripheral levels of intereulin-1RA (IL-1RA), soluble 
interleukin-2R (sIL-2R), and IL-6 and a decrease in in vitro IL-2 
secretion in SCZ patients provide the evidence of establishment 
of an inflammatory syndrome in SCZ. Kanba and Kato (2014) pro-
nounced the microglial hypothesis that activated CNS micorglia 
release proinflammatory cytokines and free radicals that cause 
abnormal neurogenesis, neuronal degradation, and white matter 
abnormalities contribute to the pathophysiology of SCZ.
There are increased concentrations of IL-6 in both patients 
with SCZ and first-episode patients, suggesting that immune 
system abnormalities may be endophenotype of SCZ. However, 
no difference in IL-6 levels compared with controls has been 
found in outpatients with stable medication and in patients 
with treatment-resistant psychosis (Miller et al., 2011). Recently, 
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García-Bueno et al. (2014) used a set of biochemical and molecu-
lar analyses to identify inflammatory pathologies in plasma and 
peripheral blood mononuclear cell samples from 117 patients 
recently diagnosed with SCZ and 106 matched controls. For 
NFκB (increased), iNOS (increased), COX2 (increased), IκBα 
(decreased), and PPAR (decreased), alterations were all indica-
tive of an active inflammatory response. In another study, IL-1, 
IL-6, and TNF cytokine networks were activated in SCZ and BD 
patients; however, only about one-half of the studies were able 
to find the activation (Brietzke et al., 2009; Kim et al., 2009; Song 
et al., 2009).
Metabolomics Overview
Metabolomics in today’s world carries on its shoulders the obli-
gation of providing a detailed picture of metabolic pathways 
and their mechanisms, whether they are in humans, animals, or 
plants. The word origin is from the Greek meta meaning change 
and nomos meaning a rule set or set of laws (Crockford et  al., 
2008). Metabolomics (also known as metabonomics or meta-
bolic profiling) is the “systematic study of the unique chemical 
fingerprints that specific cellular processes leave behind,” pre-
cisely, the study of their small-molecule metabolite (<1500 Da) 
profiles (Daviss, 2005). The metabolome denotes the collection 
of all metabolites in a biological cell, tissue, organ, or organism, 
which are the end products of cellular processes (Jordan et al., 
2009). Whereas mRNA gene expression data and proteomic 
analyses do not state the entire story of what might be hap-
pening in a cell, metabolic profiling can give an instant snap-
shot of the physiology of that cell. Even though the metabolome 
can be defined readily enough, it is not currently promising to 
analyze the complete range of metabolites by a single analyti-
cal method. In January 2007, researchers at the University of 
Alberta and the University of Calgary finished the first draft of 
the human metabolome. They assembled approximately 2500 
metabolites, 1200 drugs, and 3500 food components that can be 
presented in the human body, as described in the literature. This 
confirmation, open at the Human Metabolome Database (www.
hmdb.ca) and based on analysis of information existing in the 
current scientific literature, is far from complete (De Luca and 
St Pierre, 2000). Thus, metabolomic supplements data obtained 
from other fields such as genomics, transcriptomics, and prot-
eomics, adding a final piece to a systems approach for the study 
of disease pathophysiology, biomarker identification, and drug 
action (Quinones and Kaddurah-Daouk, 2009).
Recent developments in metabolomics are usually based on 
fast, reproducible, selective, and sensitive procedures and tech-
nologies such as gas chromatography-MS (GC-MS), capillary 
electrophoresis-mass spectroscopy, liquid chromatography-MS 
(LC-MS), and magnetic resonance spectroscopy (Zheng et  al., 
2013). Other techniques, such as electrochemistry or Fourier 
Transform Infrared Spectroscopy, have also been presumed, but 
their application is restricted by the lack of detailed structural 
information that they deliver. Generally, nuclear magnetic reso-
nance is a nondestructive technique and in spite of the over-
lapping chemical shifts for some metabolites, it is generally 
highly effective for structural explanation (Beckonert et al., 2007; 
Euceda et al., 2015). Besides the analytical technique, metabo-
lomics also uses multivariate statistical analyses (eg, principal 
component analysis, partial least-squares discriminate analysis, 
orthogonal partial least-squares discriminate analysis, cluster-
ing) to study patterns in the data (without bias) that display the 
maximum variance (Le Gall, 2015). Preferably, metabolomics will 
ultimately contribute a comprehensive map of the regulation 
of metabolic pathways and hence of the interaction of proteins 
encoded by the genome with environmental factors, including 
drug exposure.
Metabolic Signatures in Psychiatric 
Disorders
We have started to explore global metabolic prevalence and 
metabolic perturbations in psychiatric diseases. We attempt 
to ascertain biomarkers for disease, disease progression, and 
response to therapy and define pathways implicated in psychi-
atric disorders such as BD, SCZ, and addictive disorders. Table 1 
represents pathways/functions of metabolites/possible bio-
markers identified in animal model and human-based studies 
of various neuropsychiatric disorders. The examples provided 
below show how the use of advanced metabolomic platforms 
permits a global and integrated analysis of biochemical path-
ways and metabolic changes occurring in a disorder. Preferably, 
this global mapping of biochemical abnormalities would facili-
tate understating disease pathogenesis and the identification of 
clinically relevant biomarkers.
Metabolomics in BD
BD is a severe and debilitating psychiatric condition character-
ized by the alternating mood states of mania and depression. 
The pathophysiology of the disorder and the mechanism of 
action of therapies used for its treatment remain poorly under-
stood (Scola and Andreazza, 2014). Lan and colleagues (2009) 
identified increased levels of glutamate, creatine and myo-
inositol in postmortem brain tissue of BD patients as well as a 
decreased ratio of glutamate/glutamine and increased level of 
and γ-aminobutyric acid in rat brain tissue after chronic treat-
ment with valproate and lithium, respectively, suggesting that 
the equilibrium of excitory/inhibitory neurotransmission is cen-
tral to the disorder.
In another study, a plasma metabolomic analysis of BD 
patients who had received ketamine in a placebo-controlled 
crossover study showed differences in distinct biochemical 
between responsive and nonresponsive patients that were due 
to alterations in the mitochondrial β-oxidation of fatty acids, 
suggesting disease-related dysregulation of mitochondrial func-
tion and networks (Diazgranados et al., 2010; Zarate et al., 2012; 
Villaseñor et al., 2014).
Recently, a naturalistic study in 2 patients with BD type I was 
shown to determine whether biological markers (monoamine 
metabolites and BDNF) are related with the switch between 
depressive and manic states. These data suggested that the 
plasma level of 3-methoxy-4-hydroxyphenylglycol, which is 
related to noradrenaline levels in the brain, could be used as a 
biomarker of mood states in BD I (Kunita et al., 2015).
Metabolomics in SCZ
Several metabolomics studies have recently been shown in an 
effort to better define pathways modified in SCZ and its treat-
ment (Quinones and Kaddurah-Daouk, 2009; Yao et  al., 2012; 
Yang et al., 2013). Fukushima et al. (2014) identified 13 metabo-
lites differentially regulated in the serum of SCZ patients com-
pared with controls and suggest that oxidative stress may be 
involved in the pathogenesis of SCZ.
Another application of metabolomic platforms and infor-
matics tools has recognized changes in energy and neurotrans-
mitter metabolism in subregions of the dorsolateral prefrontal 
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cortex of SCZ patients (Khaitovich et  al., 2008) and in animal 
models of antipsychotic drug treatment (McLoughlin et  al., 
2009). Similarly, an interesting metabolomic study on postmor-
tem tissue offers support to the concept that aberrations at the 
level of glutamatergic neurotransmission and myelin synthesis 
play a significant role in SCZ (Tkachev et  al., 2007). However, 
most global profiling studies using postmortem brain tissue 
have been performed on subjects who have been treated with 
varying lifetime antipsychotic medication doses (Halim et  al, 
2008; Chan et al., 2011).
A recent metabolomic study evaluated serum samples from 
those with diagnoses of primary psychotic disorder (n = 45), 
other nonaffective psychosis (n = 57), affective psychosis (n = 37), 
and matched healthy controls. Increases in saturated triglycer-
ides, proline, glutamate, and lactate were identified with a highly 
significant result for proline seemingly limited to a diagnosis of 
SCZ. The lipid/glutamate profile fits with an energy metabolism 
dysfunction in SCZ with compensatory upregulation of fatty 
acid/ketone body metabolism (Orešič et al., 2011).
Still, additional support for this pathology comes from 
a metabolomics study of 112 SCZ patients and 110 healthy 
subjects (Yang et  al., 2013). Training and test sets detected 
glycerate, pyruvate, glutamate, 2-hydroxybutyrate, and myo-
inostiol. A combined classifier set of glycerate, eicosenoic acid, 
2-hydroxybutyrate, pyruvate, and cysteine profiles was found to 
be 90% accurate in diagnosing SCZ in the test set.
Metabolomics in Addictive Disorders
Several studies are ongoing to estimate signatures in addicts 
who use drug of abuse. Mapping these metabolic “signatures” 
can offer new understandings into addictive mechanisms and 
potentially identify biomarkers and therapeutic targets. Initial 
outcomes suggested that neurotransmitter pathways, purine 
pathways, and pathways concerned in oxidative stress all seem 
to be affected by cocaine or opioids (Patkar et  al., 2009). Until 
now, it was observed that cocaine changes the metabolism of 
glucose and biogenic amine differently between cerebral areas, 
being utmost in the thalamus for the glycolysis metabolome 
(Kaplan et al., 2013).
Recently, Zaitsu and colleagues (2014) examined plasma 
metabolic profiling in different drug-induced conditioned place 
preference animal models by GC-MS. They demarcated altered 
3-hydroxybutyric acid, L-tryptophan, cystine, and n-propylamine 
in morphine-addicted animals. Methamphetamine addiction 
induced significant changes in n-propylamine and lauric acid, 
whereas threonine, cystine, and spermidine levels were signifi-
cantly increased in the plasma of cocaine-addicted animals.
Further metabolomics studies in nicotine-addicted animal 
models comprise a 1H-NMR spectroscopy-based metabolomics 
analysis in 2 brain regions that explored the mechanism by 
which nicotine increased behavioral response to COC. This 
study showed that nicotine priming can supply a beneficial 
environment of metabolites for reinforcing rewarding effects of 
cocaine (Li et al., 2014a).
Another drug of abuse, heroin, is rapidly deacetylated in vivo 
(very short half-life of approximately 2–4 minutes) to an active 
metabolite, 6-acetylmorphine, which is subsequently slowly 
hydrolyzed to morphine (Dinis-Oliveira et  al., 2012). Hence, 
6-acetylmorphine has been used as the target metabolite to 
identify heroin abuse in practice, but its half-life is also short 
(approximately 30 minutes) to document heroin consumption. 
The identification of endogenous compounds that can be used 
as metabolic biomarkers of heroin abuse would represent an 
alternative approach of significant importance to detect hidden 
effects. Zheng et  al. (2013) recognized tryptophan, 5-hydroxy-
tryptamine, and 5-hydroxyindoleacetate as potential biomark-
ers of long-term heroin addiction.
Analytical Tools for Metabolome Analysis
Metabolomics tools allow us to study the metabolome, the rep-
ertoire of small molecules present in cells and tissue (Tyagi 
et al., 2010). Hundreds to thousands of metabolites can be sep-
arated and measured in samples of interest such as plasma, 
CSF, urine, or cell extracts using a diversity of commonly used 
metabolomics platforms such as NMR, GC-MS, LC-MS, and liquid 
chromatography electrochemical array detection (Milne et  al., 
2013; A Zhang et al., 2015).
The choice of metabolomic analytical instrumentation and 
software is generally goal specific, as each type of instrument 
has definite strengths. Liquid chromatography followed by cou-
lometric array detection, for example, has been used in the iden-
tification of signatures in amyotrophic lateral sclerosis (Dupuis 
et al., 2010) and Parkinson’s disease (Bogdanov et al., 2008). It is 
outstanding for mapping neurotransmitter (eg, dopamine and 
serotonin) and oxidative stress pathways. Gas chromatogra-
phy in conjunction with mass spectroscopy is often used in the 
analysis of lipid subsets (Kaddurah-Daouk et al., 2007). LC-MS 
is often used to obtain the largest possible biochemical profile 
data subset where metabolite concentrations might cover a 
broad range of information with regard to disease pathophysiol-
ogy (Adamowicz and Tokarczyk, 2015; Domingues et al., 2015). 
In addition to standard high-sample throughput applications, 
NMR spectroscopy is a quantitative nondestructive, noninvasive, 
nonequilibrium-perturbing technique that delivers comprehen-
sive data on solution-state molecular structures, including the 
atomic positions of isotopic labels (eg, 13C, 15N, or 2H) in differ-
ent isotopomers created during stable isotope tracer studies 
(Fan and Lane, 2008). For example, NMR-based high-throughput 
analysis has been successful in psychiatric patients, including 
MDD, SCZ, and BD patients (Holmes et al., 2006; Lan et al., 2009; 
Martins-de-Souza, 2014).
Future Directions as a Tool for Biomarker 
Discovery and Clinical Implications
The study of metabolism at the global or -omics’ level, stated 
as metabolomics, is a new but rapidly growing field that has 
the potential to impact our understanding of molecular mecha-
nisms of disease. It has the potential to permit mapping of early 
biochemical changes in disease and hence offers an opportunity 
to develop predictive biomarkers to major psychiatric disorders 
that can trigger earlier interventions.
Discovery of possible biomarkers for major psychiatric dis-
orders will require a paradigm shift in a biomarker discovery 
approach. Presently, the field utilizes mostly a traditional reduc-
tionist approach in which focus is given to the examination of 
individual parts and their associations to a complex condition 
(Bousman et  al., 2010). Although this approach has enhanced 
our understanding of major psychiatric disorders and helped in 
narrowing our search for possible biomarkers, it is excessively 
naive in its ability to provide robust biomarkers for complex 
phenomena in a diversity of contexts. Replication and blinded 
studies are required to confirm markers identified. Connecting 
central and peripheral changes in psychiatric disorders is cru-
cial towards defining if and how biochemical changes in plasma 
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are related to changes in the brain. Combining metabolomics 
with imaging and other -omics approaches might be powerful 
ways to achieve these goals.
The advent of a variety of biomarker discovery approaches 
moves us a step closer to identifying possible biomarkers that 
could revolutionize public health. Achieving this vision needs 
new biomarker discovery efforts that continue pushing forward 
with innovative and sound methodological strategies, minimiz-
ing limitations discussed here to avoid improper application of 
technology and over interpretation of data.
Summary and Conclusions
Psychiatric disorders are a major problem for public health 
worldwide. Development of biomarkers that could potentially 
improve diagnosis and predict treatment response or even 
the development of a mental disorder in at-risk individuals 
is a high-priority research topic. One of the major challenges 
that exists even today for the clinical diagnosis of mental dis-
orders is the phenotypical heterogeneity that probably reflects 
neurobiological heterogeneity. Also, there is a requirement of 
precise attention on rare disease research as a model to study 
personalized medicine approaches for small cohorts of subjects. 
-Omics strategies and development of clinical bioinformatics 
linking the identified molecular profiles with current clinical 
descriptions will focus on constructing a solid foundation for 
the molecular characterization of rare diseases for small patient 
populations. Longitudinal studies are needed to approve and 
expand on these initial findings.
In the future, metabolomics might be the instrumental tool 
needed to identify shared underpinnings between several psy-
chiatric diagnoses, reveal biological bases of precise symptoms, 
and ultimately implement personalized care to patients with 
psychiatric disorders (Ozomaro et al., 2013).
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